ONCO
vs
S&P 500
ONCO
S&P 500
Over the past 12 months, ONCO has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's +13% growth.
Stocks Performance
ONCO vs S&P 500
Performance Gap
ONCO vs S&P 500
Performance By Year
ONCO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Onconetix Inc
Glance View
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The firm is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The firm has Entadfi, a Food and Drug Administration (FDA) approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer.
